1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
DECEMBER 15, 1999 (DECEMBER 1, 1999)
SPECTRX, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 0-22179 58-2029543
(STATE OR OTHER JURISDICTION OF (COMMISSION FILE ( I.R.S. EMPLOYER
INCORPORATION) NUMBER) IDENTIFICATION NO.)
6025 A UNITY DRIVE, NORCROSS, GA 30071
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: 770-242-8723
- -------------------------------------------------------------------------------
(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)
2
Item 5. Other Events.
On December 1, 1999, SpectRx, Inc. announced it had entered into an
amendment to its existing agreement with Abbott Laboratories, to include joint
development of a continuous glucose monitor and pursuant to which Abbott has
increased its equity position in SpectRx, Inc. by purchasing convertible
redeemable preferred stock, as more fully described in the press release
attached hereto as Exhibit 99.1, which is hereby incorporated by reference
herein.
Item 7. Financial Statements and Exhibits.
(a) Financial statements of businesses required.
Inapplicable.
(b) Pro Forma financial information.
Inapplicable
(c) Exhibits.
The following exhibit is filed herewith:
Exhibit No. Exhibit Description
99.1 Press Release dated
December 1, 1999
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SpectRx, Inc.
Date: December 15, 1999 by: /s/ Thomas H. Muller, Jr.
--------------------------------------------
Thomas H. Muller, Jr.
Executive Vice President, Chief Financial
Officer and Secretary
4
EXHIBIT INDEX
EXHIBIT NO. EXHIBIT DESCRIPTION
- ----------- -------------------
99.1 Press Release dated December 1, 1999